Goldman Sachs Group Inc. Sells 1,250,361 Shares of Karyopharm Therapeutics Inc. $KPTI

Key Points

• Goldman Sachs Group Inc. has significantly reduced its stake in Karyopharm Therapeutics by selling 1,250,361 shares, resulting in a mere 0.99% ownership worth approximately $319,000.
• As of the latest reports, Karyopharm Therapeutics has faced analyst downgrades, with Robert W. Baird reducing its price target from $42.00 to $25.00 while maintaining an "outperform" rating.
• Karyopharm shares currently trade at $6.55, having experienced a one-year range between $3.51 and $16.95, with a reported loss of ($4.32) EPS in its latest quarter.

Goldman Sachs Group Inc. cut its stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 93.6% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 85,410 shares of the company's stock after selling 1,250,361 shares during the period. Goldman Sachs Group Inc. owned about 0.99% of Karyopharm Therapeutics worth $319,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. Two Sigma Advisers LP raised its stake in shares of Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company's stock valued at $52,000 after purchasing an additional 45,400 shares during the period. Two Sigma Investments LP grew its holdings in Karyopharm Therapeutics by 60.3% in the 4th quarter. Two Sigma Investments LP now owns 137,786 shares of the company's stock valued at $93,000 after buying an additional 51,856 shares in the last quarter. Northern Trust Corp increased its holdings in Karyopharm Therapeutics by 23.5% in the 4th quarter. Northern Trust Corp now owns 283,729 shares of the company's stock worth $192,000 after purchasing an additional 54,061 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in Karyopharm Therapeutics in the first quarter worth approximately $523,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on KPTI. Robert W. Baird reduced their price target on Karyopharm Therapeutics from $42.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, August 12th. HC Wainwright lowered shares of Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, July 16th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $34.00.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $6.55 on Friday. The stock has a market capitalization of $56.79 million, a PE ratio of -0.45 and a beta of 0.35. The business's fifty day moving average price is $5.62 and its 200-day moving average price is $5.16. Karyopharm Therapeutics Inc. has a one year low of $3.51 and a one year high of $16.95.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($4.32) EPS for the quarter, missing the consensus estimate of ($3.80) by ($0.52). The company had revenue of $37.93 million during the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current fiscal year.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.